Trucode Gene: Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System

Xconomy San Francisco — Gene-editing technology offers the potential to treat inherited disorders with selective edits and corrections to an afflicted individual’s genetic code. But with such molecular tinkering comes with the risk of unintended changes to the genome. Biotech startup Trucode Gene Repair is developing technology that it claims can edit genes in a way that reduces the risk of these so-called “off-target effects.” The South San Francisco company is announcing Tuesday that it has raised $34 million to support its research. Trucode disclosed that its investors in the financing include Kleiner Perkins and GV.